In Talc Litigation On ‘Baseless Scientific Claims,’ J&J Says Settlement Offers Plaintiffs 'Certainty’

First-Quarter Results Including 7.4% Consumer Health Sales Growth Prompt Guidance Boost

Firm reiterates stance on safety of talc as it reports 7.4% Q1 growth in consumer health product sales contributes to earnings guidance boost. It reports $3.85bn consumer health sales with US sales up 11.4% to $1.74bn and international sales 4.4% to $2.12bn.

• Source: Shutterstock

Johnson & Johnson is prepared to “put dollars towards, quite frankly, baseless scientific claims” to settle litigation alleging the talc products it previously marketed are linked to cancer.

The firm on 18 April reiterated its stance on the safety of its talc as it reported that 7.4% growth...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Earnings

More from Business